Logo image of TGEN

TECOGEN INC/WALTHAM MA (TGEN) Stock Fundamental Analysis

NYSEARCA:TGEN - NYSE Arca - US87876P2011 - Common Stock - Currency: USD

6.18  +0.28 (+4.75%)

After market: 6.2475 +0.07 (+1.09%)

Fundamental Rating

3

TGEN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 41 industry peers in the Building Products industry. TGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TGEN has reported negative net income.
TGEN had a positive operating cash flow in the past year.
TGEN had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: TGEN reported negative operating cash flow in multiple years.
TGEN Yearly Net Income VS EBIT VS OCF VS FCFTGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

1.2 Ratios

TGEN has a worse Return On Assets (-15.31%) than 87.80% of its industry peers.
TGEN has a Return On Equity of -46.53%. This is amonst the worse of the industry: TGEN underperforms 87.80% of its industry peers.
Industry RankSector Rank
ROA -15.31%
ROE -46.53%
ROIC N/A
ROA(3y)-13.51%
ROA(5y)-9.91%
ROE(3y)-30.18%
ROE(5y)-21.73%
ROIC(3y)N/A
ROIC(5y)N/A
TGEN Yearly ROA, ROE, ROICTGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

TGEN's Gross Margin of 43.64% is amongst the best of the industry. TGEN outperforms 85.37% of its industry peers.
In the last couple of years the Gross Margin of TGEN has grown nicely.
TGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.79%
GM growth 5Y3.17%
TGEN Yearly Profit, Operating, Gross MarginsTGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

4

2. Health

2.1 Basic Checks

TGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
TGEN has more shares outstanding than it did 1 year ago.
TGEN has more shares outstanding than it did 5 years ago.
TGEN has a worse debt/assets ratio than last year.
TGEN Yearly Shares OutstandingTGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
TGEN Yearly Total Debt VS Total AssetsTGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 2.82 indicates that TGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
TGEN has a Altman-Z score (2.82) which is in line with its industry peers.
The Debt to FCF ratio of TGEN is 0.63, which is an excellent value as it means it would take TGEN, only 0.63 years of fcf income to pay off all of its debts.
TGEN's Debt to FCF ratio of 0.63 is amongst the best of the industry. TGEN outperforms 95.12% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that TGEN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.18, TGEN is in the better half of the industry, outperforming 73.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.63
Altman-Z 2.82
ROIC/WACCN/A
WACC10.06%
TGEN Yearly LT Debt VS Equity VS FCFTGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.32 indicates that TGEN should not have too much problems paying its short term obligations.
TGEN has a worse Current ratio (1.32) than 82.93% of its industry peers.
TGEN has a Quick Ratio of 1.32. This is a bad value and indicates that TGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
TGEN has a worse Quick ratio (0.74) than 82.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.74
TGEN Yearly Current Assets VS Current LiabilitesTGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

TGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -220.48%.
Looking at the last year, TGEN shows a small growth in Revenue. The Revenue has grown by 2.46% in the last year.
The Revenue has been decreasing by -5.52% on average over the past years.
EPS 1Y (TTM)-220.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)2.46%
Revenue growth 3Y-9.23%
Revenue growth 5Y-5.52%
Sales Q2Q%17.68%

3.2 Future

The Earnings Per Share is expected to grow by 42.99% on average over the next years. This is a very strong growth
TGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.49% yearly.
EPS Next Y-53%
EPS Next 2Y-23.69%
EPS Next 3Y57.92%
EPS Next 5Y42.99%
Revenue Next Year-2.95%
Revenue Next 2Y8.41%
Revenue Next 3Y27.53%
Revenue Next 5Y23.49%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TGEN Yearly Revenue VS EstimatesTGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TGEN Yearly EPS VS EstimatesTGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TGEN. In the last year negative earnings were reported.
Also next year TGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TGEN Price Earnings VS Forward Price EarningsTGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TGEN is valued a bit more expensive than the industry average as 70.73% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 50.5
EV/EBITDA N/A
TGEN Per share dataTGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

TGEN's earnings are expected to grow with 57.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.69%
EPS Next 3Y57.92%

More info and screens

0

5. Dividend

5.1 Amount

TGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TECOGEN INC/WALTHAM MA

NYSEARCA:TGEN (6/18/2025, 8:04:01 PM)

After market: 6.2475 +0.07 (+1.09%)

6.18

+0.28 (+4.75%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06
Inst Owners0.05%
Inst Owner Change-96.11%
Ins Owners31.76%
Ins Owner Change2.86%
Market Cap156.11M
Analysts82.86
Price TargetN/A
Short Float %0.56%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-31.96%
Min Revenue beat(2)-33.4%
Max Revenue beat(2)-30.52%
Revenue beat(4)0
Avg Revenue beat(4)-30.88%
Min Revenue beat(4)-39.65%
Max Revenue beat(4)-19.94%
Revenue beat(8)2
Avg Revenue beat(8)-17.83%
Revenue beat(12)3
Avg Revenue beat(12)-15.77%
Revenue beat(16)4
Avg Revenue beat(16)-15.85%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.9
P/FCF 50.5
P/OCF 38.44
P/B 15.26
P/tB 29.07
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)0.12
FCFY1.98%
OCF(TTM)0.16
OCFY2.6%
SpS0.9
BVpS0.41
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.31%
ROE -46.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.64%
FCFM 13.67%
ROA(3y)-13.51%
ROA(5y)-9.91%
ROE(3y)-30.18%
ROE(5y)-21.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.79%
GM growth 5Y3.17%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.63
Debt/EBITDA N/A
Cap/Depr 175.01%
Cap/Sales 4.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.74
Altman-Z 2.82
F-Score4
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)87.45%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.94%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-220.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-53%
EPS Next 2Y-23.69%
EPS Next 3Y57.92%
EPS Next 5Y42.99%
Revenue 1Y (TTM)2.46%
Revenue growth 3Y-9.23%
Revenue growth 5Y-5.52%
Sales Q2Q%17.68%
Revenue Next Year-2.95%
Revenue Next 2Y8.41%
Revenue Next 3Y27.53%
Revenue Next 5Y23.49%
EBIT growth 1Y2.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y457.51%
FCF growth 3Y112.98%
FCF growth 5YN/A
OCF growth 1Y596.53%
OCF growth 3Y105.19%
OCF growth 5YN/A